Abstract: As the number of novel coronavirus disease (COVID-19) continues to increase, the medical situation is still critical, and potential therapeutic drugs, vaccines and stem cell replacement approaches are emerging. Chloroquine has shown better clinical antiviral efficacy than lopinavir/litonavir (clazidine) in clinical trials of small sample size. Since pharmacological action mechanism of hydroxychloroquine is similar with chloroquine and hydroxychloroquine is safer than chloroquine in the treatment of malaria and immunological diseases, the clinical pharmacology characteristics of hydroxychloroquine was reviewed, hoping to provide theoretical support for clinical effect verification of hydroxychloroquine from the perspective of clinical pharmacology and quantitative pharmacology.